Here we show that ceralasertib in combination with anti-PD-L1 demonstrates strong antitumor effects in immunocompetent mouse tumor models, even in the absence of exogenous DNA damage (e.g., IR) or sensitizing tumor molecular alterations (e.g., ATM-loss). Here, ATM is linked to neoplasm.